Monday, July 12, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

A Conversation with the Investigators: Hormonal Therapy for Prostate Cancer

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Join us on Monday, July 12th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET


Simon Chowdhury, MD, PhD
Consultant Medical Oncologist
London, United Kingdom

Tanya B Dorff, MD
Associate Clinical Professor of Medicine
City of Hope National Medical Center
Department of Medical Oncology and Developmental Therapeutics
Head, Genitourinary Cancer Program
Los Angeles, California

Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck and Sanofi Genzyme.

Optimal Integration of Androgen Receptor-Targeted Therapy into the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC)

  • Clinical and patient-specific factors in treatment decision-making for individuals with prostate-specific antigen (PSA)-only relapse after definitive surgical therapy with or without radiation therapy
  • Therapeutic approach to the management of nonmetastatic disease with further PSA progression during or after treatment with an androgen receptor-targeted agent
  • Structural composition, pharmacology, pharmacokinetics and pharmacodynamics of the next-generation antiandrogen agents apalutamide, darolutamide and enzalutamide
  • Design, eligibility criteria and key efficacy outcomes of the Phase III SPARTAN, ARAMIS and PROSPER trials of apalutamide, darolutamide and enzalutamide, respectively, for patients with nonmetastatic CRPC; FDA approvals and optimal integration into clinical management
  • Factors influencing the selection of a specific next-generation antiandrogen agent for patients with nonmetastatic CRPC
  • Spectrum, frequency, severity and monitoring of adverse events, including CNS-related toxicities, associated with apalutamide, darolutamide and enzalutamide in the SPARTAN, ARAMIS and PROSPER trials; rates of treatment discontinuation

Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

  • Biologic, clinical and patient-specific factors (eg, age, duration of therapy, extent and sites of metastases) in the selection of secondary hormonal therapy versus chemotherapy for mHSPC
  • Key efficacy and safety findings supporting the recent FDA approval of the oral gonadotropin-releasing hormone receptor antagonist relugolix for advanced prostate cancer (HERO trial); patient selection and practical integration of relugolix into clinical algorithms
  • Long-term efficacy and quality-of-life data with docetaxel or abiraterone and prednisone in combination with androgen deprivation therapy (ADT) for patients with mHSPC; current role of ADT alone
  • Design, entry criteria and key endpoints of the ongoing Phase III PEACE 1 trial of ADT with or without docetaxel, local radiation therapy and abiraterone/prednisone for patients with mHSPC; emerging results
  • Key efficacy and safety outcomes from the Phase III ARCHES and TITAN trials supporting the FDA approvals of enzalutamide and apalutamide in combination with ADT for patients with mHSPC; optimal integration into clinical practice
  • Results from the Phase III ENZAMET study evaluating enzalutamide in combination with ADT versus other nonsteroidal antiandrogen agents (bicalutamide, nilutamide or flutamide) with ADT for patients with mHSPC
  • Rationale for the inclusion of early docetaxel in the ENZAMET study; effect of earlier use of docetaxel on the efficacy and safety of enzalutamide
  • Design, entry criteria and key endpoints of the Phase III ARASENS trial of darolutamide in combination with standard ADT and docetaxel for patients with mHSPC
  • Biologic rationale for the design of the Phase III SWOG-S1216 trial evaluating ADT in combination with either orteronel or bicalutamide for newly diagnosed mHSPC
  • Optimal sequencing of systemic treatments for patients with mHSPC; incorporation of local treatment of the primary tumor and metastases into the management plan

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives

  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer, and apply this information in the recommendation of nonresearch treatment options for patients.
  • Appraise the similarities and differences among commercially available next-generation antiandrogen agents to personalize therapy selection for patients.
  • Explore available data with cytotoxic and secondary hormonal therapy for hormone-sensitive metastatic prostate cancer to effectively design treatment plans for patients.
  • Recognize the adverse events associated with hormonal agents commonly employed in the management of prostate cancer, and develop strategies to prevent, mitigate and manage these toxicities.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Chowdhury has no relevant conflicts of interest to disclose. The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Dr DorffAdvisory Committee: AbbVie Inc, Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Janssen Biotech Inc; Consulting Agreements: Dendreon Pharmaceuticals Inc, Janssen Biotech Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Pfizer Inc. Dr SmithAdvisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Merck and Sanofi Genzyme.